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LETTERS TO THE EDITOR
LHRH analogues and breast cancer
Sir - A very welcome recent editorial in the Journal (Smith,
1991) addressed the important question of the use of LHRH
analogues in breast cancer, but we do not consider all of the
viewpoints expressed to be either definitive or necessarily
correct: Firstly, the word analogues is used throughout as
being synonymous with LHRH agonists. This is now a
historical viewpoint as pure LHRH antagonists are now
available for clinical study and, although still experimental,
the problems of the early antagonist compounds (viz short
half-life and histamine release) seem to be overcome with
newer agents (Bajuez et al., 1988). The ability to produce an
immediate 'medical castration' without any transient initial
stimulation phase, may be considered an advance for both
breast and prostate cancer therapy.
Results of suppression of DNA synthesis and inhibition of
cell growth of 'oestrogen-independent' MDA-MB-231 cell
line by LHRH antagonists (Sharoni et al., 1989) and excel-
lent inhibition of mouse MXT mammary tumour (Szende et
al., 1990) suggest another possible role for LHRH antagon-
ists in the treatment of human breast cancer.
The statement that 'oophorectomy is already a redundant
treatment', as an editorial comment in the Journal on breast
cancer management, cannot be allowed to pass unchallenged.
The two randomised trials cited (Buchanan et al., 1986; Ingle
et al., 1986) to support the notion that tamoxifen is as
effective as oophorectomy do not ' . . . show ... that tamox-
ifen is as effective as oophorectomy in every respect and with
minimal toxicity', they only found no significant difference in
response rates in favour of one or other of the two treat-
ments in studies of low statistical power. Further, all the
tamoxifen treated patients later relapsed and, at this time, the
physicians were left with potentially endocrine sensitive
cancer patients with premenopausal levels of oestrogens cir-
culating, proven by crossover oophorectomy responses.
We would draw further attention to other studies (e.g.,
Mathe et al., 1987), including those analysing effects of
tamoxifen on endometrium and the rare but increased inci-
dence of uterine cancer in patients treated with tamoxifen
(Fornander et al., 1989), tamoxifen flare (Hartley et al., 1987)
and relative merits of different endocrine therapies (Rose &
Mouridsen, 1988).
In the treatment of human breast cancer there is an opti-
mal sequence of hormone manipulations and it would be
agreed by all that tamoxifen therapy is, for all individuals,
near the top. However, with their immediate action, effective-
ness in inducing 'medical castration' with no side effects and
possible direct action on tumour cells, newer LHRH anta-
gonists deserve more basic and clinical research in the treat-
ment of breast cancer.
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